Skip to content

SomaServe- successful closing of £2m late seed funding round

SomaServe Ltd, a pioneer in nanomedicines for crossing biological barriers today announced that it has completed a highly successful, oversubscribed late seed funding of £2.1m. SomaServe has also secured further IP and global commercial rights to PolyNaut® platform technology (the…

Abcam and SomaServe partnership

Abcam and SomaServe announce comprehensive partnership to realise the potential of PolyNaut® ‘bionic’ nanoparticles for delivery to live cells.  Commercialise novel cell delivery platform technology Develop novel delivery methods for research applications Revolutionise utility of live cell imaging to explore disease…

Back To Top